Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | BCL2 | P10415 | 2/20 | 0.42 |
| ▸ | BECN1 | Q14457 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | LATS1 | O95835 | 4/20 | 0.41 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15919362 | 0.86 | ACP1 (0.56) | MEN1KMT2AACACBACACABRD9 | |
| SCHEMBL15905078 | 0.83 | MEN1 (0.51) | MEN1KMT2AACACBACACAMAPT | |
| SCHEMBL15919364 | 0.76 | ACACB (0.50) | MEN1KMT2AACACBACACAACP1 | |
| SCHEMBL15905538 | 0.75 | PLA2G2A (0.56) | MEN1KMT2A | |
| SCHEMBL15919424 | 0.75 | PIP4K2A (0.50) | MEN1KMT2ALATS1MAPT | |
| SCHEMBL30601010 | 0.75 | MAP4K1 (0.44) | CYP17A1BRD9LATS1 | |
| SCHEMBL15919508 | 0.74 | ACACB (0.48) | MEN1KMT2AACACBACACAMAPT | |
| SCHEMBL4992131 | 0.74 | NPSR1 (0.54) | MEN1KMT2AMAPTCYP3A4CYP2C9 | |
| SCHEMBL15919376 | 0.73 | ACACB (0.43) | MEN1KMT2AACACBACACAMAPT | |
| SCHEMBL15919433 | 0.73 | KMT2A (0.56) | MEN1KMT2AMAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | MEN1 511/4885KMT2A 1886/4885CYP17A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.